Syndax Pharmaceuticals Inc (SNDX) saw its loss widen to $12.97 million, or $0.71 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $10.33 million, or $2.85 a share.
Revenue during the quarter was stable at $0.30 million, when compared with the previous year period.
Operating loss for the quarter was $13.18 million, compared with an operating loss of $8.75 million in the previous year period.
"Our pipeline of innovative therapeutic candidates for cancer continues to make meaningful progress, and the recent melanoma results, as well as the expansion of ENCORE 601 into colorectal cancer, highlight the potential application of entinostat to a broad range of cancers. We believe the substantial unmet medical need in melanoma patients who have failed treatment with a PD-1 antagonist represents a fast to market opportunity for an effective and well tolerated therapy, and we look forward to presenting updated results from the melanoma cohort of ENCORE 601 at ASCO. In addition, we have secured a Type B meeting with the FDA in late June to discuss the development path for entinostat in melanoma," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "Later this quarter, we anticipate determining whether either of the non-small cell lung cancer cohorts have met the prespecified criteria to advance to the second stage of the trial."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
